Understanding the Impact of a Sanofi-Aventis/Genzyme Merger: PharmaLive Special Report
NEWTOWN, Pa., January 28, 2011 - The Paris-based pharma behemoth, Sanofi-Aventis, lead the second-largest health-care acquisition of 2010 with its proposed purchase of Genzyme Corp., one of the world’s leading biotech players. The European Union has recently announced its approval for the proposed $18.5 billion deal, however, the deal has been held up as Genzyme considers the $69 per share offer as too low. Industry insiders speculate that this deal will soon be worked out.
Product diversification remains a significant growth strategy in the pharma world as demonstrated by 2010’s largest healthcare M&A transaction, Novartis AG’s acquisition of Alcon Inc. For a total of $51.6 billion, Novartis will merge Alcon into its fold and become the premiere player in the worldwide eye-health arena.
Alcon and Novartis have attractive worldwide eye-care activities, each offering their own competitive positions in highly complementary segments that combined cover more than 70% of the global vision-care market. Aligning these strengths will create an offering of even more compelling products for patients around the globe. According to Novartis, the new eye-care division will have enhanced opportunities to accelerate expansion in high-growth regions, generate greater value from combined product portfolios, and capitalize on strengthened R&D capabilities.
The merger is anticipated to be finalized during first-half 2011. Implementation is expected to take six months from the closing of the merger. Following the completed merger, Alcon will be the new eye-care division of Novartis. The business will include CIBA Vision and ophthalmic medicines.
Boston Scientific continues to show commitment in providing the broadest portfolio of less-invasive devices for cardiovascular care. Boston Scientific recently acquired Atritech, a privately held company based in Plymouth, Minn. This deal is centered around Atritech's newest product, a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The $375 million deal is anticipated to be completed in the first quarter of 2011.
More information is available in Mergers & Acquisitions, Partnerships, & Collaborations Review & Outlook, available at www.pharmalive.com/special_reports
For additional information, contact Sandra Baker at +1-215-944-9836 or Sandra.Baker@ubm.com.
About UBM Canon Data Products
UBM Canon Data Products provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries through PharmaLive Special Reports and Appliance Market Research Reports; maintains eKnowledgeBase and MDRWeb, comprehensive market intelligence tools serving the pharmaceutical, biotechnology, and medical-device sectors; and manages company-wide Site Licenses for PharmaLive.com, Med Ad News, and R&D Directions.
About UBM Canon
UBM Canon is a business-to-business media company serving the worldwide advanced manufacturing sector through its publications, trade events, and electronic media.
Posted: January 2011
Recommended for you